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Abnormal Savda Munziq (ASMq) is a herbal preparation used in Traditional Uighur Medicine for the treatment and prevention
of diabetes, cardiovascular diseases, chronic asthma and cancer. The recommended dose of this decoction for cancer patients
is 500mL administered orally three times a day. Our approach aimed at reducing the high amount of ﬂuid intake required
by fractionation of ASMq guided by the antiproliferative activity on HL-60 cells. The fractionation of ASMq resulted in
the preparation of an active extract, Extr-4. Using solid phase extraction, Extr-4 was further fractionated into ﬁve fractions
(SPE-0, SPE-20, SPE-40, SPE-60 and SPE-80), with SPE-40 showing the strongest antiproliferative activity. Caﬀeic acid, rutin,
isoquercitrin, isorhamnetin 3-O-rutinoside, apigenin 7-O-glucoside, rosmarinic acid, luteolin and formononetin were identiﬁed
in Extr-4 and fractions thereof by means of TLC, HPLC-DAD and LC-MS. SPE-40 contained the main compounds responsible
for the antiproliferative activity on HL-60 cells. Thus, a phenolic fraction with high antiproliferative activity on HL-60 cells was
obtained from ASMq through the bioassay-guided fractionation process. This could provide a better pharmaceutical formulation
that minimizes the administration inconveniencies of a high volume (1.5L per day) of ASMq decoction for cancer patients.
1.Introduction
Abnormal Savda Munziq (ASMq) is a medicinal herbal
preparation used in the traditional Uighur medicine in
Xinjiang region of China [1]. ASMq includes ten medicinal
species represented by Cordia dichotoma Forst. f., Anchusa
italica Retz., Glycyrrhiza uralensis Fisch., Adiantum capillus-
veneris L., Euphorbia humifusa Willd., Ziziphus jujuba Mill.,
Lavandula angustifolia Mill., Foeniculum vulgare Mill., Me-
lissa oﬃcinalis L., and Alhagi pseudoalhagi Desv. The mix-
ture is administered as a decoction and is regularly used for
the prevention and treatment of diabetes, cardiovascular
diseases, chronic asthma, and cancer. For liver, stomach, and
colon cancer, the recommended dose of the decoction is
500mL three times a day [2].
Recent studies have shown that ASMq can signiﬁcantly
inhibit the growth and viability of Hep G2 human hepatoma
cell line [2–4]. ASMq has also been reported to scavenge free
radicals [1]. In addition, some species included in ASMq
were reported to show in vitro inhibitory activity on diﬀerent
tumor cell lines. For example, G. uralensis inhibited the
growth of Hep3B human hepatoma [3]a n dM C F - 7b r e a s t
cancer cell line [4]. M. oﬃcinalis exerted inhibitory activity
against continuous cell culture of HEp-2 cells derived from
human laryngeal cancer [5], HeLa, and MCF-7 cell lines [6].
Z. jujuba decreased the viability of Hep G2 cell line [7].
Some of these species also showed in vitro antiproliferative
activities on HL-60 cell line [8].
Although the eﬀect of ASMq and species included in
its composition has been recorded on diﬀerent cancer cells,
the high administration volume of the preparation (1.5L
per day) is not only inconvenient for the patients, but also
adds with a high percentage to the daily recommended ﬂuid
intake. The European Food Safety Authority recommends a
drinking volume of around 1.5L per day. In the USA, The
Food and Nutrition Board 2004 states a required amount of
ﬂuid intake (water and beverages) of 3L per day for adult
m e na n d2 . 2Lp e rd a yf o ra d u l tw o m e n[ 9–11].2 Evidence-Based Complementary and Alternative Medicine
Thus, the consumption of 1.5L day−1 of ASMq would
represent around 100% of the required ﬂuid intake as
considered by the European forums and around 50% of
the American recommended ﬂuid intake. Therefore, reduc-
ing the volume of ASMq decoction, while preserving the
antiproliferative eﬀect of the mixture, would provide a more
convenient modern formulation for the treatment of cancer
patients.Thepresentstudyaimedatobtainingahighlyactive
antiproliferative fraction of ASMq using bioassay-guided
fractionation and cell viability evaluation.
2. Experimental
2.1. Plant Materials. Pobumuguo (fruits of C. dichotoma),
Niushecao (whole plant of A. italica), Gancao (root of G. ura-
lensis), Tiexianjue (whole plant of A. capillus-veneris), Diji-
ncao (whole plant of E. humifusa), Hongzao (fruits of Z.
jujuba), Xunyicao (aerial part of L. angustifolia), Xiaohui-
xiang (fruits of F. vulgare), Mifenghua (whole plant of M.
oﬃcinalis), and Citang (sugar secretion from A. pseudo-
alhagi)werepurchasedfromXinjiangHospitalofTraditional
Uighur Medicine, Urumqi, China in September 2007. The
plant material used was unprocessed.
2.2. Chemicals and Reagents. Luteolin, rosmarinic acid,
apigenin 7-O-glucoside and isorhamnetin 3-O-rutinoside
were obtained from Extrasynth` ese (Genay, France), caﬀeic
acid from Sigma-Aldrich (St. Louis, Mo, USA), and for-
mononetin, rutin, isoquercitrin and gallic acid from Carl
Roth (Karlsruhe, Germany). Acetonitrile (HPLC grade) was
purchased from VWR International (Leuven, Belgium).
Glacial acetic acid (purity > 99.8%) and DMSO were
obtained from Carl Roth (Karlsruhe, Germany). Folin-
Ciocalteu’s phenol reagent was purchased from Merck
(Darmstadt, Germany), HPD-300 macroporous resin from
Cang Zhou Bonchem Co., Ltd. (Hebei, China), Polyamide
resin from Taizhou Luqiao Biochemical Corporation (Zhe-
jiang, China), SPE Mega Bond Elut C-18 cartridges from
Varian (Middelburg, The Netherlands). TLC silica gel 60 F254
plates were obtained from Merck (Darmstadt, Germany). All
o t h e rr e a g e n t su s e dw e r eo fa n a l y t i c a lg r a d e .
2.3. Preparation and Fractionation
2.3.1. Preparation of ASMq. ASMq was prepared according
to a previously reported procedure [12]. The plant material
was separately ground and mixed in the following ratio:
C. dichotoma (10.6), A. italica (10.6), G. uralensis (7.1),
A. capillus-veneris (4.9), E. humifusa (4.9), Z. jujuba (4.9),
L. angustifolia (4.9), F. vulgare (4.9), M. oﬃcinalis (4.9),
and A. pseudoalhagi (42.3). The mixture was decocted in
boiling water in a ratio of 1:10 (w/v) for 3h. After ﬁltration,
the residue was reextracted for 3h, two times in the same
volume of boiling water. The resulting crude extract was
ﬁltered, evaporated to dryness under reduced pressure, and
pulverized. The obtained powder was used for this study.
The yield was 39.9% (w/w) with respect to the total mass of
dry materials.
2.3.2. Preparation of Diﬀerent Extracts of ASMq. 350g dry
extract of ASMq was dissolved in 1050mL hot H2O( 6 0 ◦C),
ﬁltered, and cooled to room temperature. The resulting
solutionwaspassedthroughacolumn(125cm ×5cm)ﬁlled
with HPD-300 macroporous adsorbent resin. The column
w a se l u t e dw i t h3b e dv o l u m e s( B V )o fH 2O dest. The H2O
eluate was concentrated, and then 95% EtOH was added to
obtain a ﬁnal concentration of 70% EtOH. The mixture was
stirredfor10min.Theresultingprecipitatewascollectedand
redissolved in H2O and the EtOH precipitation was repeated
once again. The resulting precipitate was decolored with
activated carbon and evaporated under reduced pressure to
obtain extract 1 (Extr-1, 54.9g). The HPD-300 macroporous
column was sequentially eluted with 3BV of 20% EtOH and
3BV of 60% EtOH, and the resulting eluates were collected
separately and evaporated under reduced pressure to dryness
to obtain extract 2 (Extr-2, 15.7g) and extract 3 (Extr-3,
25.3g), respectively. The yields (w/w) of Extr-1, Extr-2, and
Extr-3 were 15.69%, 4.49%, and 7.23% of the dry weight of
ASMq, respectively.
2.3.3. Preparation of Extract 4. Dry extract of ASMq (350g)
was dissolved in 1050mL hot H2O( 6 0 ◦C) and ﬁltered.
1.5 volumes of 95% EtOH were added; the mixture was
stirred for 20min and then allowed to stand for 24h.
The resulting supernatant layer was ﬁltered, concentrated
under reduced pressure to 350mL and subjected to column
chromatography (125cm × 5cm) on polyamide resin. The
c o l u m nw a se l u t e dﬁ r s tw i t hH 2O dest. (3BV), followed
by 60% EtOH (3BV). The fraction eluted with H2O dest.
was discarded, while the fraction eluted with 60% EtOH
was evaporated under reduced pressure to dryness to obtain
extract 4 (Extr-4, 12.2g). The yield (w/w) of Extr-4 was
3.49% with respect to the dry weight of ASMq.
2.3.4.FractionationofExtr-4. Extr-4wasfurtherfractionated
by solid phase extraction (SPE). 50mg of Extr-4 were
dissolved in 1mL MeOH 40% and applied onto an SPE
column preconditioned with 2 reservoir volumes (RV)
MeOH and 2RV H2O. The cartridge was sequentially eluted
with 2RV of H2O and 20%, 40%, 60%, and 80% MeOH at a
ﬂ o wr a t eo f1m Lm i n −1. The resulting eluates were collected
separately and evaporated under reduced pressure to yield
SPE-0 (1.1mg), SPE-20 (1.0mg), SPE-40 (11.7mg), SPE-
60 (11.9mg) and SPE-80 (5.2mg), respectively. The yields
(w/w) of these fractions were 0.15% (SPE-0), 0.14% (SPE-
20), 1.63% (SPE-40), 1.66% (SPE-60), and 0.73% (SPE-80)
of the dry weight of ASMq, respectively.
A ﬂow chart of the ASMq preparation and fractionation
procedure is shown in Figure 1.
2.4.CellCulture. TheHL-60humanpromyelocyticleukemia
cell line was obtained from the American Type Culture
Collection (ATCC). Cell medium RPMI 1640 and its supple-
ments were obtained from Life Technologies, Inc., USA. The
HL-60 cells were routinely cultured in RPMI 1640 medium,
supplemented with 10% (v/v) heat inactivated foetal bovineEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: A ﬂow chart of the ASMq preparation and fractionation procedure.
serum,1%L-glutamine,and1%penicillin/streptomycinand
grown in a humidiﬁed atmosphere with 5% CO2 at 37◦C.
2.5. Evaluation of Cell Viability. Cells were seeded at a
density of 0.1 × 106 cells mL−1 in 12-well plates and grown
for 24h. Cells were then incubated with 100μgmL −1 and
250μgmL −1 ASMq, extracts (Extr-1, Extr-2, Extr-3, and
Extr-4) and 50μgmL −1 SPE fractions (SPE-0, SPE-20, SPE-
40, SPE-60, and SPE-80), respectively. In order to determine
the IC50 value of Extr-4, cells were exposed to increasing
concentrations(0,25,50,100,200,and250μgmL −1)ofExtr -
4. Prior to use, the stock solutions of all dry extracts (ASMq
extracts and SPE fractions) were prepared in 60% EtOH
and then ﬁltered through 0.20μm sterile syringe ﬁlters. The
ﬁnal concentration of EtOH in culture medium during the
treatment of cells did not exceed 0.5% (v/v). Vehicle-treated
cells (0.5% EtOH) were tested as control samples. After 24h,
48h, and 72h of incubation, the cells were stained with
tryptan blue (0.4%) and counted with a cell counter (Vi-
CELL XR Cell Viability Analyzer, Beckman, USA). The cell
viability was expressed as the percentage of control. Analyses
were performed in triplicate, values are given as mean ± SD.
2.6. TLC Analysis. T L Ca n a l y s e so fA S M qe x t r a c t sa n dS P E
fractions were performed on silica gel 60 F254 plates. Extr-1,
Extr-2,Extr-3,andExtr-4weredissolvedinH2O,20%EtOH,
40% EtOH, and 60% EtOH, respectively (20mgmL−1), and
10μL aliquots were applied to a TLC plate. As mobile phase
CHCl3/MeOH/H2O (70:22:3.5, v/v/v) was used, the plate
was sprayed with 0.5% fast blue salt B aqueous solution [13].
Evaluation was done under visible light. Rosmarinic acid was
used as reference compound.
SPE fractions were dissolved in 60% MeOH (20mg
mL−1)a n d5 μLa l i q u o t sw e r ea p p l i e dt oaT L Cp l a t ea n d
developed with EtOAc/HCOOH/HAc/H2O (100:11:11:26,
v/v/v/v). The plate was then sprayed with natural products
spraying reagent (1% methanolic diphenylboric acid-β-
ethylamino ester) followed by 5% ethanolic polyethylene
glycol-4000 [13]. The plate was investigated under 365nm.
Rutin, hyperoside, and astragalin were used as reference
compounds.
2.7. HPLC-DAD and LC-MS Analysis. HPLC-DAD analyse
was conducted on a Shimadzu LC-10AD liquid chromato-
graph equipped with a SCL-10A system operator, a SPD-
M20A diode array detector, a SIL-10AD auto injector and a
DGU-14A degasser. The LC-MS analyses were performed on
an UltiMate 3000 RSLC-series system (Dionex, Germering,
Germany) coupled to a 3D quadrupole ion trap mass
spectrometerequippedwithanorthogonalESIsource(HCT,
Bruker Daltonics, Bremen, Germany). HPLC separation was
carried out on a Hypersil BDS-C18 column (4 × 250mm,
5μm, Thermo Scientiﬁc, Waltham, Mass, USA) at a ﬂow rate
of 1.2mLmin−1. Water (pH 2.8 with acetic acid) and MeCN
(with the same amount of acetic acid) were used as mobile
phase A and B, respectively. The following gradient program
wasused:15%B(0min),41.3%B(45min),95%B(46min),
and 95% B (51min). The eluent ﬂow was split roughly 1:8
before the ESI ion source, which was operated as follows:
capillary voltage: 3.7kV, nebulizer: 30psi (N2), dry gas ﬂow:
8Lmin −1 (N2), and dry temperature: 340◦C. The mass
spectrometer was operated in an automated data-dependent
acquisition (DDA) mode where each MS scan (m/z 80–
1100, average of 5 spectra) was followed by MS2 scans (m/z
40–1100, average of 3 spectra, isolation window of 4Th,4 Evidence-Based Complementary and Alternative Medicine
fragmentation amplitude of 1.0V) of the two most intense
precursor ions, and MS3 scans (m/z 40–1100, average of 3
spectra, isolation window of 4Th, fragmentation amplitude
of 1.0V) of the most intense fragment ion in each MS2
scan. In additional LC-MS experiments, the instrument was
operated in alternating ion MS1 mode.
The sample injection volume was 10μL. 2 mg of Extr-4
as well as 2mg of each of the SPE fractions were separately
sonicated with 1mL of 60% MeOH-DMSO (4:1, v/v) for
5min at room temperature. Standard phenolic compounds
were dissolved in MeOH. Identiﬁcation of compounds was
achieved by comparing retention times as well as UV and
MSn spectra.
2.8.TotalFlavonoidContent. Thetotalﬂavonoidcontentwas
determined by aluminium nitrate method [14]. 30mg of
ASMq and 3mg of Extr-4 were dissolved in 1mL H2Oa n d
1mL of 60% EtOH in a 5mL volumetric ﬂask, respectively.
2mLofH 2O and 0.15mL of aqueous 5% NaNO2 solution
were added, followed by 0.15mL of 10% Al(NO3)3 6min
later. The mixture was allowed to stand for another 6min
at room temperature. Then, 1mL of 1M NaOH was added.
The sample was immediately diluted with H2Ot oaﬁ n a l
volume of 5mL and mixed. A blank without sample solution
was prepared in parallel. Rutin was used as standard to
establish the calibration curve. Absorbances of samples were
determined at 510nm on a spectrophotometer (Beckman
DU-640). Total ﬂavonoid content was expressed as mg rutin
equivalent (RUE) g−1 dried extract. Data for ASMq and
Extr-4 were reported as mean ± SD for ﬁve replicates and
for triplicates, respectively.
2.9.TotalPhenolicContent. TheFolin-Ciocalteumethodwas
used to determine the total phenolic content [15]. 160μL
of sample (6mg ASMq dissolved in 1mL H2Oa n d0 . 6m g
Extr-4dissolvedin1mL60%EtOH,respectively)wereadded
to a 5mL volumetric ﬂask and diluted with H2O dest.
to 2.5mL. 0.25mL of Folin-Ciocalteu reagent were added.
6min later, 0.75mL of 20% aqueous Na2CO3 solution were
added, diluted with H2Ot oaﬁ n a lv o l u m eo f5 m La n d
mixed. After incubation at room temperature for 2h, the
absorbance of the reaction mixture was measured at 765nm
against a blank containing only solvent and reagents. Gallic
acid was used as standard for the calibration curve. Total
phenolic content was expressed as mg gallic acid equivalent
(GAE) g−1 dried extract. Data for ASMq and Extr-4 were
reported as a mean ±SDforﬁvereplicatesandfortriplicates,
respectively.
2.10.StatisticalAnalysis. Theresultsofcellviabilitywerepre-
sented as means ± SD. Statistical comparison was performed
using the one-way analysis of variance (ANOVA) followed by
Tukey’s test (in case of equal variance) or Dunnett’s T3 test
(in case of unequal variance). These tests were performed
using SPSS 13 for Windows. P<0.05 was considered
statistically signiﬁcant. IC50 values and their 95% conﬁdence
limits were estimated by a sigmoidal dose-response model
with variable slope (GraphPad Prism software, version 4.03).
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Figure 2: Eﬀect of ASMq, Extr-1, Extr-2, Extr-3, and Extr-4 on the
viability of HL-60 cells. Cells were seeded in 12-well plates, grown
for 24h and then treated with 100μg/mL and 250μg/mL ASMq,
Extr-1, Extr-2, Extr-3, and Extr-4. After 24h, 48h, and 72h cell
viability was assessed by tryptan blue exclusion method. Data rep-
resent the percentage of control value and are expressed as mean ±
SD of triplicate cultures. ∗P<0.05, as compared to control cells.
3. Results and Discussion
In the ﬁrst step of this study, three extracts, Extr-1, Extr-
2, and Extr-3, were obtained from ASMq by macroporous
resin chromatography and tested for their eﬀect on cell
viability. Figure 2 shows the activity of ASMq and the
corresponding extracts on HL-60 cell viability. ASMq and
Extr-1 (250μgmL −1) showed no remarkable cytotoxicity
after 72h, reducing cell viability to 87.1 ± 16.7% and 87.7 ±
1.3%, respectively. Extr-1 enhanced cell proliferation after
24h for both tested concentrations (100 and 250μgm L −1).
ASMq was previously reported to contain 58% saccharides
as glucose equivalents [16]. Therefore, the enhanced cell
proliferation of HL-60 cells after 24h in the presence of Extr-
1 could be due to the high content of saccharides in these
extracts. Unlike ASMq and Extr-1, Extr-2 (250μgmL −1)
showedhighercytotoxicity,inducingadeclineincellviability
to 64.8 ± 4.8%, while Ext-3 (250μgmL −1) exhibited the
highest cytotoxicity, decreasing cell viability to 50.83 ±
0.70%after72h.Thus,ASMqshowednoremarkableactivity
on HL-60 cell proliferation at the given concentration, while
diﬀerent eﬀects on cell viability were distributed between the
three extracts obtained from ASMq, with the most apolar of
the extracts showing increased antiproliferative eﬀect. The
low activity of ASMq is in line with the high dose of ASMq
decoction(1.5Lperda y)requiredforthetreatmentofcancer
patients. The result of TLC analysis revealed that phenolic
compounds were absent in Extr-1 but could be detected
in Ext-2 and Extr-3. When compared to Extr-2, Extr-3
showed an enriched phenolic ﬁngerprint. This implied a
possible correlation between the phenolic compounds and
the cytotoxic activity on HL-60 cells. Therefore, a polyamide
chromatography was performed on ASMq to obtain an
extract enriched in phenolic compounds. The resultingEvidence-Based Complementary and Alternative Medicine 5
extract, Extr-4, showed higher cytotoxicity than Extr-2 and
Extr-3, reducing cell viability to 5.29 ± 0.28% at a concentra-
tion of 250μgmL −1, after 72h (Figure 2). Figure 3 shows the
dose-response curve for Extr-4 when tested on HL-60 cells
aft e r24h,48h,and72h.TheIC 50 valueswere105.7μgmL −1
(24h), 95.1μgmL −1 (48h) and 72.3μgmL −1 (72h).
According to preliminary TLC analysis, the number
of phenolic compounds increased from Extr-1 to Extr-4
with the majority present in the latter. The total ﬂavonoid
content and total phenolic content of ASMq were 25 ±
1mgRUEg−1 dried extract and 38 ± 1mgGAEg−1 dried
extract, respectively, whereas those of Extr-4 were 221 ±
9mgRUEg−1 dried extract and 333 ± 7mgGAEg−1 dried
extract, respectively. Both the ﬂavonoid content and the
phenolic content increased to approximately 9-fold in Extr-4
versus ASMq. These results conﬁrmed that the phenolic
compoundswereenrichedinExtr-4throughpolyamideresin
chromatography.
Using SPE, Extr-4 was further fractionated into ﬁve
fractions, SPE-0, SPE-20, SPE-40, SPE-60, and SPE-80.
According to cell viability assessment after 72h, all fractions
showed various degrees of cytotoxicity on HL-60 cells
(Figure 4). SPE-40 (50μgmL −1) was found to exhibit the
strongest inhibitory eﬀect on the viability of HL-60 cells by
inducing a time-dependent decrease in cell viability to 8.2 ±
1.5%. The TLC analyses revealed the presence of ﬂavonoids
inallSPEfractionsexceptSPE-80.Themajorityofﬂavonoids
were present in SPE-40, implying that ﬂavonoids may be the
most active phenolic compounds in SPE-40.
The identiﬁcation of phenolic compounds in Extr-4 and
SPE fractions was performed using HPLC-DAD and LC-
MS. The HPLC chromatogram of Extr-4 recorded at 254 nm
is shown in Figure 5. Eight phenolic compounds, namely,
caﬀeic acid (1), rutin (2), isoquercitrin (3), isorhamnetin
3-O-rutinoside (4), apigenin 7-O-glucoside (5), rosmarinic
acid (6), luteolin (7), and formononetin (8), were identiﬁed
in Extr-4 by comparison of their retention time, and UV
and MS spectral characteristics to those of standards in
Figure 5(a), as well as by spiking the sample with standards.
The chemical structures of compounds 1∼8 are shown
in Figure 6. Several phenolic compounds that have been
described as chemical constituents of the species included in
ASMq, such as chlorogenic acid, luteolin 3 ,7-O-diglucoside,
ferulic acid, eriodictyol 7-O-glucoside, narirutin, rhamnetin,
rhoifolin, and isovitexin, were not found in Extr-4. Some of
the phenolic compounds we identiﬁed in Extr-4 by LC-MS
were also found in SPE-0, SPE-20, SPE-40, and SPE-60. For
example, 1, 2, and 6 were identiﬁed in SPE-0 (Figure 7(a))
and SPE-20 (Figure 7(b)) in varying ratios. Five phenolic
compounds, 2–6, were identiﬁed in SPE-40 (Figure 7(c)),
whereas 4, 7, and 8 were found in SPE-60 (Figure 7(d)).
Compound 3 was identiﬁed only in SPE-40. Based on the
results of TLC and HPLC analyses, SPE-80 may not contain
phenolic compounds (Figure 7(e)) but is mainly enriched in
licoricetriterpenesaponins(e.g.,glycyrrhizicacid)according
to tentative identiﬁcation by LC-MS (data not shown).
Phenolic compounds are well studied secondary plant
metabolites that have been thoroughly investigated due
to their presence in the human diet and their biological
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Figure 3: Dose-response curves of antiproliferative activity of
Extr-4 after 24h (a), 48h (b), and 72h (c). HL-60 cells were
cultured in 12-well plates for 24h to reach logarithmic growth
phase and then incubated with 25–250μg/mL Extr-4. Cell viability
was estimated by tryptan blue staining and cell counting after
24h, 48h, and 72h. Data are presented as percentage of control
value. The horizontal axis represents a log scale of concentration
of Extr-4. The IC50 was calculated using a sigmoidal dose-response
model with variable slope. The curve represents the average of
experiments performed in triplicate. ∗P<0.05, compared with
respective control value (24h:100.00 ± 8.50%; 48h:100.00 ±
8.84%, 72h:100.00 ± 22.26%).6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Viability of HL-60 cells after 24h, 48h, and 72h
of treatment with SPE-0, SPE-20, SPE-40, SPE-60, and SPE-80
subfractions. Cell viability was assessed by tryptan blue exclusion
method and is presented as percentage of control value. Data are
expressed as mean ± SD of two independent experiments, each of
which was done in triplicate. ∗P<0.05, compared with control.
Each sample was tested at a concentration of 50μg/mL.
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Figure 5: Reversed phase HPLC chromatograms of standard
phenolic compounds (a) and Extr-4 (b) at a wavelength of 254nm.
(1)c a ﬀeic acid, (2) rutin, (3) isoquercitrin, (4) isorhamnetin 3-
O-rutinoside, (5) apigenin 7-O-glucoside, (6) rosmarinic acid, (7)
luteolin, and (8) formononetin.
properties, including their beneﬁcial eﬀects on health. One
of these eﬀects is their capacity to interfere with all stages
of the cancer process [17, 18]. Several ﬂavonoids have been
shown to suppress carcinogenesis in various animal models
[19]. A growing number of epidemiological studies suggest
that high ﬂavonoid intake may be correlated with decreased
cancer risk [20–22].
The phenolic compounds detected in Extr-4 and its SPE
fractions were also previously identiﬁed in species from the
composition of ASMq. For example, 1 was identiﬁed in L.
angustifolia [23]a n dM. oﬃcinalis [24], 2 in Z. jujuba [25],
A. capillus-veneris [26], C. dichotoma [27], G. uralensis [28],
and F. vulgare [29], and 3 in A. capillus-veneris [26], G.
uralensis [28], and M. oﬃcinalis [30]. 4 was found in C.
dichotoma [27], G. uralensis [28], and F. vulgare [29]a n d5
in E. humifusa [31]a n dM. oﬃcinalis[30]. 6 was identiﬁed in
C. dichotoma [27], F. vulgare [29], and M. oﬃcinalis [24]. 7
and 8 were found in M. oﬃcinalis [32]a n dG. uralensis [33],
respectively.
Compounds 2 [34]a n d8 [35] were reported to possess
no remarkable cytotoxicity on HL-60 cells. 4 showed no
distinctive cytotoxicity on HT-29 human colon carcinoma,
MCF-7 human breast carcinoma, and Hep G2 human
hepatomacelllines[36].3showedantiproliferativeeﬀectson
B16F10 murine melanoma [37]a n dM C F - 7h u m a nb r e a s t
carcinoma cell lines [38]. 5 possessed moderate cytotoxic
eﬀects on human prostate cancer cell lines derived from
diﬀerent metastatic sites, such as LNCaP, DU145, and PC-
3 cells [39]. 1 [40]a n d6 [41] showed low cytotoxic eﬀects
on HL-60 cell line, while 7 [42] exhibited a strong cytotoxic
activity on HL-60 cells. Thus, the phenolic compounds
identiﬁed in Extr-4 have been previously shown to have no
remarkable (2, 4, 8), moderate (1, 3, 5, 6), or strong (7)
cytotoxic eﬀect on diﬀerent cancer cell lines.
SPE-0 and SPE-20 contain compounds that have been
described as moderate cytotoxic which can explain their
observed activity in the viability tests. The concentration
of 7, a strong cytotoxic compound, in SPE-60 was low
as shown by the HPLC analysis, justifying the moderate
eﬀect of this fraction. The characterization of SPE-40, the
most active fraction, identiﬁed compounds described as
moderate (3, 5, 6) or very low cytotoxic (2, 4), suggesting
that 3, 5, and 6 could, at least in part, contribute to the
antiproliferative activity of SPE-40 on HL-60 cells. The
mechanisms of antiproliferative eﬀects of these compounds
were investigated in some studies. For example, 3 was
reported to reduce glioblastoma cell growth without induc-
ing apoptosis, possibly by modulating the control of the
cell cycle. It was also suggested that β-catenin-mediated
signaling may be involved on the antiproliferative activity of
3 [43]. 5 inhibited cancer cell growth through deconjugation
of glycosides that occurs in the cellular compartment to
produce aglycone and apigenin [44]. Apigenin itself exhibits
a signiﬁcant growth inhibition against hepatoma cell lines
and induces apoptosis in Hep G2 cells [45]. Its apoptotic
mechanism might be mediated through the p53-dependent
pathwayandtheinductionofp21expression[45]orthrough
a mitochondria/caspase-pathway [46]. It was also reported
thatapigenininhibitscancercellproliferationthroughG2/M
cellcyclearrest [47]andErβ [48].Theauthorshavefoundno
report on the mechanism underlining the antiproliferative
activity of 6 against cancer cells.
However, these results also imply that the identiﬁed
phenolics are not the only compounds responsible for
the antiproliferative activity of SPE-40 and suggest the
possible presence of one or more compounds with stronger
activity. The latter could contribute to the cytotoxicity of
the identiﬁed phenolic compounds by both additive and
synergistic eﬀects. The majority of the uncharacterized com-
pounds in SPE-40 showed UV-Vis spectral characteristics
similar to ﬂavanones, chalcones, and ellagic acid derivatives
(data not shown), which were reported to possess strong
antiproliferative activities on diﬀerent cancer cells [49–52].
This could also be conﬁrmed by LC-MS, which indicates theEvidence-Based Complementary and Alternative Medicine 7
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presence of several typical liquorice ﬂavanones (e.g., liquir-
itin apioside, liquiritin, and liquiritigenin) and chalcones
(e.g., isoliquiritin apioside and isoliquiritin) based on the
comparison of multistage MS data with published results
(data not shown) [53], indicating that phenolic compounds,
withpossiblestrongantiproliferativeactivity,constitutemost
of the remaining uncharacterized compounds in SPE-40.
4. Conclusion
In summary, our study focused on the bioassay-guided
fractionation of ASMq aiming at the reduction of the
administration volume of the ASMq decoction (1.5L day−1)
and the modernization of its pharmaceutical formulation.
Four extracts, namely, Extr-1, Extr-2, Extr-3, and Extr-4,
were prepared from ASMq. Extr-4 exerted the strongest
antiprolifertive activity on HL-60 cells. Extr-4 was further
fractionated into ﬁve fractions by solid phase extraction, of
which SPE-40 showed the strongest inhibitory eﬀect on HL-
60 cells. The results of the cell viability assay, quantiﬁcation
assay, and the TLC and LC-MS analyses on Extr-4 and the
SPE fractions revealed that the main bioactive components
with antiproliferative activity against HL-60 cell line could
be phenolic compounds. The substances identiﬁed in Extr-4
and its SPE fractions were caﬀeic acid, rutin, isoquercitrin,
isorhamnetin 3-O-rutinoside, apigenin 7-O-glucoside, ros-
marinic acid, luteolin, and formononetin. Isoquercitrin,
apigenin 7-O-glucoside, and rosmarinic acid may contribute8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: HPLC chromatograms of ﬁve SPE fractions at a wave-
length of 254nm. (a) SPE-0, (b) SPE-20, (c) SPE-40, (d) SPE-
60, (e) SPE-80, (1)c a ﬀeic acid, (2) rutin, (3) isoquercitrin, (4)
isorhamnetin 3-O-rutinoside, (5) apigenin 7-O-glucoside, (6)
rosmarinic acid, (7) luteolin, and (8) formononetin.
to the cytotoxicity of SPE-40 on HL-60 cells. The results also
suggest that other compounds than the identiﬁed phenolics
addtotheantiproliferativeeﬀectofASMq.However,fraction
SPE-40obtainedinthecourseofourworkcouldsigniﬁcantly
reduce the high therapeutic dosage of ASMq (500mL three
times a day). One dose of ASMq was reduced from 500mL
(∼200g dry weight) to 1.6g fraction SPE-40. Thus, the
bioassay-guided fractionation of ASMq could lead to the
enrichment of active compounds in an active fraction and
to the diminution of the administration dose of the TCM
preparation, providing a better pharmaceutical formulation
for cancer patients.
Acknowledgments
The ﬁrst author is thankful to Eurasia Paciﬁc Uninet for
providing the scholarship. This research work is part of the
project “Quality Assurance of Herbal Medicinal Products
(HMPs) from TCM”, aided by the Austrian Federal Ministry
of Science and Research and the Federal Ministry for Health,
Family, and Youth and was also funded by the Cultivation
Fund of the Key Scientiﬁc and Technical Innovation Project
MinistryofEducation,China(no.708058).Theauthorswish
to present their acknowledgements also to Katharina Tscher-
now for her contribution to the fractionation of Extr-4.
References
[ 1 ] A .Y u s u p ,H .U p u r ,A .U m a r ,a n dN .M o o r e ,“ P r o t e ct i v ee ﬀects
of Munziq and Mushil of abnormal Savda to mitochondrial
oxidativedamage,”Fundamental&ClinicalPharmacology,vol.
18, no. 4, pp. 471–476, 2004.
[2] H. Upur, A. Yusup, I. Baudrimont et al., “Inhibition of
cell growth and cellular protein, DNA and RNA synthesis
in human hepatoma (HepG2) cells by ethanol extract of
abnormal Savda Munziq of traditional Uighur medicine,”
Evidence-Based Complementary and Alternative Medicine, vol.
2011, Article ID 251424, 9 pages, 2011.
[ 3 ]W .T .C h u n g ,S .H .L e e ,a n dJ .D .K i m ,“ E ﬀe c to ft h ee x t r a c t s
from Glycyrrhiza uralensis Fisch on the growth characteristics
of human cell lines: anti-tumor and immune activation
activities,” Cytotechnology, vol. 37, no. 1, pp. 55–64, 2001.
[4] E. H. Jo, H. D. Hong, and N. C. Ahn, “Modulations of the Bcl-
2/Bax family were involved in the chemopreventive eﬀects of
licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human
breast cancer cell,” Journal of Agricultural & Food Chemistry ,
vol. 52, no. 6, pp. 1715–1719, 2004.
[ 5 ]A .A l l a h v e r d i y e v ,N .D u r a n ,S .C e t i n e r ,a n dM .O z g u v e n ,
“Investigation of the anticancerogenic eﬀect of the essential
oil of Melissa oﬃcinalis L,” Pharmaceutical & Pharmacological
Letters, vol. 11, no. 1, pp. 26–29, 2001.
[6] J. Canadanovi´ c-Brunet, G. Cetkovi´ c, S. Djilas et al., “Radical
scavenging, antibacterial, and antiproliferative activities of
Melissa oﬃcinalis L. extracts,” Journal of Medicinal Food, vol.
11, no. 1, pp. 133–143, 2008.
[7] X. Huang, A. Kojima-Yuasa, T. Norikura, D. O. Kennedy, T.
Hasuma, and I. Matsui-Yuasa, “Mechanism of the anti-cancer
activity of Zizyphus jujuba in HepG2 cells,” American Journal
of Chinese Medicine, vol. 35, no. 3, pp. 517–532, 2007.
[8] M. Kizaibek, B. Kopp, S. Prinz, S. Popescu, and H. Upur,
“Antiproliferative activity of individual herbs of abnormal
savda Munziq on HL-60 cells,” Keji Daobao, vol. 27, pp. 94–
98, 2009.
[9] M. J. Bossingham, N. S. Carnell, and W. W. Campbell,
“Water balance, hydration status, and fat-free mass hydration
in younger and older adults,” American Journal of Clinical
Nutrition, vol. 81, no. 6, pp. 1342–1350, 2005.
[10] EFSA, “Draft dietary reference values for water,” Scientiﬁc
Opinion of the Panel on Dietetic Products, Nutrition and
Allergies, 2008.
[11] E. J´ equier and F. Constant, “Water as an essential nutrient: the
physiological basis of hydration,” European Journal of Clinical
Nutrition, vol. 64, no. 2, pp. 115–123, 2010.
[12] A. Yusup, H. Upur, I. Baudrimont et al., “Cytotoxicity of
abnormal savda Munziq aqueous extract in human hepatoma
(HepG2)cells,”Fundamental&ClinicalPharmacology,vol.19,
no. 4, pp. 465–472, 2005.
[13] H. Wagner and S. Bladt, Plant Drug Analysis: A Thin Layer
Chromatography Atlas, Springer, 1996.
[14] Committee CP, Pharmacopoeia of the P. R. China, Chemical
Industry Press, Beijing, China, 2005.
[15] Y.Y.SoongandP.J.Barlow,“Antioxidantactivityandphenolic
content of selected fruit seeds,” Food Chemistry, vol. 88, no. 3,
pp. 411–417, 2004.Evidence-Based Complementary and Alternative Medicine 9
[16] M. Kizaibek, H. Upur, and K. Amut, “Determination of total
saccharides and total saponins in abnormal savda Munziq,”
Keji Daobao, vol. 27, pp. 39–42, 2009.
[17] G. G. Duthie, S. J. Duthie, and J. A. M. Kyle, “Plant poly-
phenols in cancer and heart disease: implications as nutri-
tional antioxidants,” Nutrition Research Reviews, vol. 13, no.
1, pp. 79–106, 2000.
[18] P. C. H. Hollman, “Evidence for health beneﬁts of plant
phenols: local or systemic eﬀects?” Journal of the Science of
Food & Agriculture, vol. 81, no. 9, pp. 842–852, 2001.
[19] J. D. Lambert, J. Hong, G. Y. Yang, J. Liao, and C. S. Yang,
“Inhibition of carcinogenesis by polyphenols: evidence from
laboratory investigations,” The American Journal of Clinical
Nutrition, vol. 81, no. 1, pp. 284S–291S, 2005.
[20] R. Garcia-Closas, C. A. Gonzalez, A. Agudo, and E. Riboli,
“Intake of speciﬁc carotenoids and ﬂavonoids and the risk of
gastric cancer in Spain,” Cancer Causes & Control, vol. 10, no.
1, pp. 71–75, 1999.
[21] P. Knekt, J. Kumpulainen, R. Jarvinen et al., “Flavonoid intake
and risk of chronic diseases,” American Journal of Clinical
Nutrition, vol. 76, no. 3, pp. 560–568, 2002.
[22] L.LeMarchand,S.P.Murphy,J.H.Hankin,L.R.Wilkens,and
L. N. Kolonel, “Intake of ﬂavonoids and lung cancer,” Journal
of the National Cancer Institute, vol. 92, no. 2, pp. 154–160,
2000.
[23] C. Proestos, N. Chorianopoulos, G. J. E. Nychas, and M.
Komaitis, “RP-HPLC analysis of the phenolic compounds
of plant extracts. Investigation of their antioxidant capacity
and antimicrobial activity,” Journal of Agricultural & Food
Chemistry, vol. 53, no. 4, pp. 1190–1195, 2005.
[24] B. Klimek, T. Majda, J. Gora, and J. Patora, “Investigation of
essential oil and phenolic compounds of lemon balm (Melissa
oﬃcinalisL.)cultivatedinPoland,”HerbaPolonica,vol.44,pp.
324–331, 1998.
[25] C. Souleles and G. Shammas, “Flavonoids from the leaves of
Zizyphus jujuba,” Fitoterapia, vol. 59, p. 154, 1988.
[26] F. Imperato, “New phenolic glycosides in the fern adiantum
capullis-veneris L,” Chemistry & Industry, pp. 957–958, 1982.
[27] Y. Wang, K. Ohtani, R. Kasai, and K. Yamasaki, “Flavonol
glycosides and phenolics from leaves of Cordia dichotoma,”
Natural Medicines, vol. 50, no. 5, p. 367, 1996.
[ 2 8 ]S .S .J i a ,C .M .M a ,Y .H .L i ,a n dJ .H .H a o ,“ G l y c o s i d e so f
phenolic acid and ﬂavonoids from the leaves of Glycyrrhiza
uralensis Ficsh,” Yao Xue Xue Bao, vol. 27, no. 6, pp. 441–444,
1992.
[29] I. Parejo, O. Jauregui, F. S´ anchez-Rabaneda, F. Viladomat,
J. Bastida, and C. Codina, “Separation and characterization
of phenolic compounds in fennel (Foeniculum vulgare)
using liquid chromatography-negative electrospray ionization
tandem mass spectrometry,” Journal of Agricultural & Food
Chemistry, vol. 52, no. 12, pp. 3679–3687, 2004.
[30] A. Mulkens and I. Kapetanidis, “Flavonoids from leaves
of Melissa oﬃcinalis L. (Lamiaceae),” Pharmaceutica Acta
Helvetiae, vol. 62, no. 1, pp. 19–22, 1987.
[31] W. Z. Liu, H. Wang, and L. Kong, “Studies on chemical
constituents of Euphorbia humifusa,” Zhong Cao Yao, vol. 32,
pp. 107–108, 2001.
[32] T. Mencherini, P. Picerno, C. Scesa, and R. Aquino, “Trite-
rpene, antioxidant, and antimicrobial compounds from Me-
lissa oﬃcinalis,” Journal of Natural Products, vol. 70, no. 12,
pp. 1889–1894, 2007.
[33] H. Bai, D. Dou, Y. Pei, Y. Chen, and L. Wu, “Isolation and
structure identiﬁcation of chemical constituents in cultivated
Glycyrrhiza uralensis,” Zhong Cao Yao, vol. 36, pp. 652–654,
2005.
[34] S. C. Shen, Y. C. Chen, F. L. Hsu, and W. R. Lee, “Diﬀerential
apoptosis-inducing eﬀect of quercetin and its glycosides
in human promyeloleukemic HL-60 cells by alternative
activation of the caspase 3 cascade,” Journal of Cellular
Biochemistry, vol. 89, no. 5, pp. 1044–1055, 2003.
[35] T. H. Kang, S. J. Jeong, W. G. Ko et al., “Cytotoxic lavandulyl
ﬂavanones from Sophora ﬂavescens,” Journal of Natural
Products, vol. 63, no. 5, pp. 680–681, 2000.
[36] M. L. Xu, G. Li, D. C. Moon et al., “Cytotoxicity and DNA
topoisomerase inhibitory activity of constituents isolated
from the fruits of Evodia oﬃcinalis,” Archives of Pharmacal
Research, vol. 29, no. 7, pp. 541–547, 2006.
[37] L. O. Regasini, A. A. Lopes, D. H. S. Silva et al., “Antipro-
liferative eﬀect of Pterogyne nitens on melanoma cells,”
Revista de Ciencias Farmaceuticas Basica Aplicada, vol. 28, no.
3, pp. 335–340, 2007.
[ 3 8 ]J .C .L eB a i l ,F .V a r n a t ,J .C .N i c o l a s ,a n dG .H a b r i o u x ,
“Estrogenic and antiproliferative activities on MCF-7 human
breast cancer cells by ﬂavonoids,” Cancer Letters, vol. 130, no.
1-2, pp. 209–216, 1998.
[39] J. K. Srivastava and S. Gupta, “Antiproliferative and apoptotic
eﬀects of chamomile extract in various human cancer cells,”
Journal of Agricultural & Food Chemistry, vol. 55, no. 23, pp.
9470–9478, 2007.
[40] E. Sergediene, K. J¨ onsson, H. Szymusiak, B. Tyrakowska,
I. M. C. M. Rietjens, and N. Cenas, “Prooxidant toxicity
of polyphenolic antioxidants to HL-60 cells: description of
quantitative structure-activity relationships,” FEBS Letters,
vol. 462, no. 3, pp. 392–396, 1999.
[41] A.Nitzsche,S.V.Tokalov,H.O.Gutzeit,andJ.Ludwig-M¨ uller,
“Chemical and biological characterizition of cinnamic acid
derivatives from cell cultures of lavender (Lavandula oﬃci-
nalis) induced by stress and jasmonic acid,” Journal of Agricul-
tural & Food Chemistry, vol. 52, no. 10, pp. 2915–2923, 2004.
[42] W. G. Ko, T. H. Kang, S. J. Lee, Y. C. Kim, and B. H. Lee,
“Eﬀects of luteolin on the inhibition of proliferation and
induction of apoptosis in human myeloid leukaemia cells,”
Phytotherapy Research, vol. 16, no. 3, pp. 295–298, 2002.
[43] N. G. Amado, D. M. Cerqueira, F. S. Menezes, J. F. Mendes da
Silva, V. M. Neto, and J. G. Abreu, “Isoquercitrin isolated from
hyptis fasciculata reduces glioblastoma cell proliferation and
changes β-catenin cellular localization,” Anti-Cancer Drugs,
vol. 20, no. 7, pp. 543–552, 2009.
[44] J. K. Srivastava and S. Gupta, “Extraction, characterization,
stability and biological activity of ﬂavonoids isolated from
chamomile ﬂowers,” Molecular & Cellular Pharmacology, vol.
1, no. 3, pp. 138–147, 2009.
[45] L.C.Chiang,L.T.Ng,I.C.Lin,P.L.Kuo,andC.C.Lin,“Anti-
proliferative eﬀect of apigenin and its apoptotic induction
in human Hep G2 cells,” Cancer Letters, vol. 237, no. 2, pp.
207–214, 2006.
[46] E. J. Choi and G. H. Kim, “Apigenin induces apoptosis
through a mitochondria/caspase-pathway in human breast
cancer MDA-MB-453 cells,” Journal of Clinical Biochemistry
and Nutrition, vol. 44, no. 3, pp. 260–265, 2009.
[47] M. B. Ujiki, X. Z. Ding, M. R. Salabat et al., “Apigenin inhibits
pancreatic cancer cell proliferation through G2/M cell cycle
arrest,” Molecular Cancer, vol. 5, article 76, 2006.10 Evidence-Based Complementary and Alternative Medicine
[48] P. Mak, Y. K. Leung, W. Y. Tang, C. Harwood, and S. M.
Ho, “Apigenin suppresses cancer cell growth through ERβ,”
Neoplasia, vol. 8, no. 11, pp. 896–904, 2006.
[49] C. Pouget, F. Lauthier, A. Simon et al., “Flavonoids: structural
requirements for antiproliferative activity on breast cancer
cells,” Bioorganic & Medicinal Chemistry Letters, vol. 11, no.
24, pp. 3095–3097, 2001.
[50] T. Takahashi, M. Kobori, H. Shinmoto, and T. Tsushida,
“Structure-activity relationships of ﬂavonoids and the induc-
tion of granulocyticor monocytic-diﬀerentiation in HL60
human myeloid leukemia cells,” Bioscience, Biotechnology &
Biochemistry, vol. 62, no. 11, pp. 2199–2204, 1998.
[ 5 1 ]J .N .L o s s o ,R .R .B a n s o d e ,A .T r a p p e y ,H .A .B a w a d i ,a n d
R. Truax, “In vitro anti-proliferative activities of ellagic
acid,” Journal of Nutritional Biochemistry, vol. 15, no. 11, pp.
672–678, 2004.
[52] M. Cabrera, M. Simoens, G. Falchi et al., “Synthetic chalcones,
ﬂavanones, and ﬂavones as antitumoral agents: biological
evaluation and structure-activity relationships,” Bioorganic &
Medicinal Chemistry, vol. 15, no. 10, pp. 3356–3367, 2007.
[53] G. Tan, Z. Zhu, H. Zhang et al., “Analysis of phenolic
and triterpenoid compounds in licorice and rat plasma
by high-performance liquid chromatography diode-array
detection, time-of-ﬂight mass spectrometry and quadrupole
ion trap mass spectrometry,” Rapid Communications in Mass
Spectrometry, vol. 24, no. 2, pp. 209–218, 2010.